AR054368A1 - Metodo para tratar hiperlipidemia - Google Patents

Metodo para tratar hiperlipidemia

Info

Publication number
AR054368A1
AR054368A1 ARP060102234A ARP060102234A AR054368A1 AR 054368 A1 AR054368 A1 AR 054368A1 AR P060102234 A ARP060102234 A AR P060102234A AR P060102234 A ARP060102234 A AR P060102234A AR 054368 A1 AR054368 A1 AR 054368A1
Authority
AR
Argentina
Prior art keywords
hyperlipidemia
squalene synthase
inhibitor
hmg
effective amount
Prior art date
Application number
ARP060102234A
Other languages
English (en)
Inventor
T Nashimoto
R Tozawa
T Wada
E Ishikawa
T Nishi
H Iino
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR054368A1 publication Critical patent/AR054368A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se provee una composicion farmacéutica util para prevencion y/o tratamiento de hiperlipidemia que comprende la combinacion de una cantidad eficaz de inhibidor de sintasa de escualeno y del inhibidor de reductasa HMG-CoA. Reivindicacion 1: Un método para prevenir y/o tratar hiperlipidemia caracterizado por que comprende administrar a un mamífero afectado con hiperlipidemia una combinacion de una cantidad eficaz de inhibidor de sintasa de escualeno y inhibidor de reductasa HMG- CoA. Reivindicacion 17: La utilizacion de inhibidor de sintasa de escualeno para la fabricacion de una composicion farmacéutica para prevenir y/o tratar hiperlipidemia, caracterizada por que comprende la combinacion de una cantidad eficaz de inhibidor de sintasa de escualeno y del inhibidor de reductasa HMG-CoA.
ARP060102234A 2005-06-01 2006-05-30 Metodo para tratar hiperlipidemia AR054368A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68587105P 2005-06-01 2005-06-01
US72832905P 2005-10-20 2005-10-20

Publications (1)

Publication Number Publication Date
AR054368A1 true AR054368A1 (es) 2007-06-20

Family

ID=36699172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102234A AR054368A1 (es) 2005-06-01 2006-05-30 Metodo para tratar hiperlipidemia

Country Status (17)

Country Link
US (1) US20090209510A1 (es)
EP (1) EP1962832A2 (es)
JP (1) JP2008542191A (es)
KR (1) KR20080012916A (es)
AR (1) AR054368A1 (es)
AU (1) AU2006253255A1 (es)
BR (1) BRPI0610484A2 (es)
CA (1) CA2609784A1 (es)
CR (1) CR9521A (es)
IL (1) IL187207A0 (es)
MA (1) MA29531B1 (es)
MX (1) MX2007014730A (es)
NO (1) NO20076566L (es)
PE (1) PE20070603A1 (es)
RU (1) RU2007149337A (es)
TW (1) TW200714280A (es)
WO (1) WO2006129859A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
NZ587019A (en) * 2008-01-10 2012-07-27 Takeda Pharmaceutical Capsule formulation
CA2868372A1 (en) 2011-04-08 2012-10-11 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
RU2543485C2 (ru) * 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI760067B (zh) * 2020-08-13 2022-04-01 友霖生技醫藥股份有限公司 固態口服醫藥組成物
US11833133B2 (en) 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
WO1994007485A1 (en) * 1992-10-06 1994-04-14 Merck & Co., Inc. Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith
RU2040932C1 (ru) * 1993-12-17 1995-08-09 Крестьянское хозяйство "Агрофирма Дижа" Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения
EP0862562B1 (en) * 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP3479796B2 (ja) * 1995-09-13 2003-12-15 武田薬品工業株式会社 ベンゾオキサゼピン化合物
AU2401697A (en) * 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US20030078251A1 (en) * 2000-06-23 2003-04-24 Masakuni Kori Benzoxazepinones and their use as squalene synthase inhibitors
CA2428669A1 (en) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. High-density lipoprotein-cholesterol level elevating agent
EP1249230B1 (de) * 2001-04-12 2003-11-05 Vesifact Ag Coenzym Q10 enthaltende Mikroemulsion-Prekonzentrate und Mikroemulsionen
CA2451163A1 (en) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Agent for preventing or treating organ functional disorders and order dysfunction
WO2004064865A1 (ja) * 2003-01-17 2004-08-05 Takeda Pharmaceutical Company Limited 骨格筋保護剤

Also Published As

Publication number Publication date
WO2006129859A3 (en) 2007-04-19
US20090209510A1 (en) 2009-08-20
WO2006129859A2 (en) 2006-12-07
TW200714280A (en) 2007-04-16
EP1962832A2 (en) 2008-09-03
PE20070603A1 (es) 2007-06-22
JP2008542191A (ja) 2008-11-27
IL187207A0 (en) 2008-06-05
NO20076566L (no) 2008-02-22
CA2609784A1 (en) 2006-12-07
KR20080012916A (ko) 2008-02-12
MA29531B1 (fr) 2008-06-02
CR9521A (es) 2008-02-22
MX2007014730A (es) 2008-02-15
RU2007149337A (ru) 2009-07-10
AU2006253255A1 (en) 2006-12-07
BRPI0610484A2 (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR054368A1 (es) Metodo para tratar hiperlipidemia
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CR10680A (es) Composiciones de inhibidores de chk1
EA200800064A1 (ru) Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
ATE460164T1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
ATE544866T1 (de) Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
CL2009000647A1 (es) Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
BRPI0922301A2 (pt) combinações de inibidor de hsp90
EA200601746A1 (ru) Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс"
AR055810A1 (es) Uso de inhibidores de acetilcolinesterasa e inhibidores de la produccion de beta-app o acumulacion de a-beta
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
EA200802364A1 (ru) Композиция для ухода за кожей и ее применение
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
AR069144A1 (es) Inhibidores del complemento c1q para la prevencion y el tratamiento del glaucoma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal